Details for New Drug Application (NDA): 213879
✉ Email this page to a colleague
The generic ingredient in DABIGATRAN ETEXILATE MESYLATE is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the dabigatran etexilate mesylate profile page.
Summary for 213879
Tradename: | DABIGATRAN ETEXILATE MESYLATE |
Applicant: | Msn |
Ingredient: | dabigatran etexilate mesylate |
Patents: | 0 |
Pharmacology for NDA: 213879
Mechanism of Action | Thrombin Inhibitors |
Medical Subject Heading (MeSH) Categories for 213879
Suppliers and Packaging for NDA: 213879
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
DABIGATRAN ETEXILATE MESYLATE | dabigatran etexilate mesylate | CAPSULE;ORAL | 213879 | ANDA | Novadoz Pharmaceuticals LLC | 72205-202 | 72205-202-34 | 6 BLISTER PACK in 1 CARTON (72205-202-34) / 10 CAPSULE in 1 BLISTER PACK |
DABIGATRAN ETEXILATE MESYLATE | dabigatran etexilate mesylate | CAPSULE;ORAL | 213879 | ANDA | Novadoz Pharmaceuticals LLC | 72205-202 | 72205-202-60 | 60 CAPSULE in 1 BOTTLE (72205-202-60) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 75MG BASE | ||||
Approval Date: | May 22, 2024 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 150MG BASE | ||||
Approval Date: | May 22, 2024 | TE: | AB | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 110MG BASE | ||||
Approval Date: | Aug 12, 2024 | TE: | AB | RLD: | No |
Complete Access Available with Subscription